PT  - JOURNAL ARTICLE
AU  - Hitchings, Matt D.T.
AU  - Ranzani, Otavio T.
AU  - Lind, Margaret L.
AU  - Dorion, Murilo
AU  - D’Agostini, Tatiana Lang
AU  - de Paula, Regiane Cardoso
AU  - de Paula, Olivia Ferreira Pereira
AU  - de Moura Villela, Edlaine Faria
AU  - Scaramuzzini Torres, Mario Sergio
AU  - de Oliveira, Silvano Barbosa
AU  - Schulz, Wade
AU  - Almiron, Maria
AU  - Said, Rodrigo
AU  - de Oliveira, Roberto Dias
AU  - da Silva, Patricia Vieira
AU  - de Araújo, Wildo Navegantes
AU  - Gorinchteyn, Jean Carlo
AU  - Dean, Natalie E.
AU  - Andrews, Jason R.
AU  - Cummings, Derek A.T.
AU  - Ko, Albert I.
AU  - Croda, Julio
TI  - Change in COVID-19 risk over time following vaccination with CoronaVac: A test-negative case-control study
AID  - 10.1101/2021.12.23.21268335
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.23.21268335
4099  - http://medrxiv.org/content/early/2021/12/24/2021.12.23.21268335.short
4100  - http://medrxiv.org/content/early/2021/12/24/2021.12.23.21268335.full
AB  - Objective To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil.Design Test negative case-control study.Setting Community testing for covid-19 in São Paulo state, Brazil.Participants Adults aged 18-120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021.Main outcome measures RT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection.Results From 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 test-negative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14-41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98-125 days, 1.55 (1.16 to 2.07) from 126-153 days, 1.56 (1.12 to 2.18) from 154-181 days, and 2.12 (1.39-3.22) from 182 days.Conclusions In the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac.What is already known on this topic- The effectiveness of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) against moderate and severe covid-19 has been demonstrated in clinical trials and observational studies.- Observational studies have suggested that effectiveness of other covid-19 vaccines appears to decrease over time, prompting many countries to deploy additional doses for individuals who have completed their primary series.- There is currently no evidence for change in the rate of breakthrough infection in individuals who have received a primary series of CoronaVac.What this study adds- In individuals receiving two doses of CoronaVac, the odds of symptomatic covid-19 increased over time since series completion.- Larger increases in covid-19 odds were observed in individuals aged 18-40, and in healthcare workers compared to non-healthcare workers.- Odds of covid-19 hospitalisation or death increased over time since series completion, but to a lesser extent.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful for the Pan American Health Organization's support and the São Paulo State in making the databases available for analysis. JC is supported by the Oswaldo Cruz Foundation (Edital Covid-19 - resposta rápida: 48111668950485). OTR is funded by a Sara Borrell fellowship (CD19/00110) from the Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program and from the Generalitat de Catalunya through the CERCA Program. This work was supported by grant R01-AI139761 from the National Institute for Allergy and Infectious Diseases to N.E.D.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee for Research of Federal University of Mato Grosso do Sul (CAAE: 43289221.5.0000.0021). The Free and Informed Consent form was waived because the study involved de-identified surveillance datasets.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified databases as well as the R codes will be deposited in the repository https://github.com/juliocroda/VebraCOVID-19 https://github.com/juliocroda/VebraCOVID-19